
|Articles|June 1, 2001
5-FU cream formulation displays unique profile
Washington - The new 5-fluorouracil (5-FU) 0.5 percent topical cream (Carac) indicated for the treatment of actinic keratoses offers more targeted drug delivery along with the potential for a more favorable safety profile than a previously available formulation containing a 10-fold higher concentration of active ingredient, according to results from comparative studies presented at the annual meeting of the American Academy of Dermatology.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
4
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
5














